Literature DB >> 12957680

Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis.

Tomi S Mikkola1, Mary S Anthony, Thomas B Clarkson, Richard W St Clair.   

Abstract

The efflux of cholesterol from cells and its incorporation into HDL is believed to be the initial step in reverse cholesterol transport. This report addresses the question of whether there is a relationship between the ability of serum to promote efflux of cholesterol from cells in culture and the severity of coronary artery atherosclerosis (CAA). Surgically postmenopausal cynomolgus monkeys (n=142) were treated for 2-years with conjugated equine estrogens (CEE), CEE plus medroxyprogesterone acetate, or two different doses of tibolone, a synthetic steroid. CAA was determined at necropsy, and the cholesterol efflux potential of serum from each animal was determined using 3H-cholesterol-labeled Fu5AH cells and human skin fibroblasts in culture. A significant negative correlation was seen between CAA and cholesterol efflux from Fu5AH cells (r=-0.44, P< or =0.0001), but not skin fibroblasts. Although there was a wide range of plasma HDL cholesterol concentrations in these animals (10-81 mg/dl), using multiple regression analysis, LDL+VLDL cholesterol and the serum cholesterol efflux potential were the only significant independent predictors of CAA, explaining 41.6 and 10.7% of the variability (P<0.0001), respectively. Thus, the potential of serum to promote cholesterol efflux from Fu5AH cells may represent a useful independent measure for improving the assessment of CAA risk.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957680     DOI: 10.1016/s0021-9150(03)00247-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity.

Authors:  Hagai Tavori; Alexandra M Fenton; Deanna L Plubell; Sara Rosario; Elisabeth Yerkes; Rayna Gasik; Joshua Miles; Paige Bergstrom; Jessica Minnier; Sergio Fazio; Nathalie Pamir
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

2.  Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Authors:  Amir Hooshang Mohammadpour; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

3.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 4.  Postmenopausal tibolone therapy: biologic principles and applied clinical practice.

Authors:  Morris Notelovitz
Journal:  MedGenMed       Date:  2007-01-03

5.  Communication-Microelectrode Detection of Cholesterol Efflux from the Human Buccel Mucosa.

Authors:  Xiaochun Yu; Thomas J Kelley; Hillel J Chiel; James D Burgess
Journal:  J Electrochem Soc       Date:  2016-06-07       Impact factor: 4.316

6.  HDL-apoA-I exchange: rapid detection and association with atherosclerosis.

Authors:  Mark S Borja; Lei Zhao; Bradley Hammerson; Chongren Tang; Richard Yang; Nancy Carson; Gayani Fernando; Xiaoqin Liu; Madhu S Budamagunta; Jacques Genest; Gregory C Shearer; Franck Duclos; Michael N Oda
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

7.  Endothelial lipase and reverse cholesterol transport in type 2 diabetes mellitus.

Authors:  Sammy Wm Shiu; Huali Zhou; Ying Wong; Kathryn Cb Tan
Journal:  J Diabetes Investig       Date:  2010-06-01       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.